Upfront Briefing
Three flavors of "capital is back" before lunch. GSK reminded the tape that late-stage oncology still trades at full sticker, Parabilis reminded it the IPO window has hinges again, and AstraZeneca reminded everyone it's quietly been in the obesity race the whole time. GSK's $10.6B for Nuvalent is the biggest check it's written in a decade; Parabilis' $670M debut is the biggest biotech IPO ever, full stop; and AZ's oral GLP-1 just printed numbers that should make the orforglipron crowd glance over a shoulder. Different stories, same punchline — the money is there for assets that are actually de-risked.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,387 |
(0.3%) |
+8.0% |
| Nasdaq 100 |
29,085 |
(1.1%) |
+16.7% |
| Russell 2000 |
2,867 |
+0.4% |
+13.8% |
| Healthcare (XLV) |
152.6 |
(0.2%) |
(1.8%) |
| Biotech (XBI) |
131.4 |
+2.3% |
+5.7% |
| Nasdaq Biotech (NBI) |
5,873 |
+1.5% |
+1.4% |
| Clinical Trials (BBC) |
41.4 |
+1.3% |
+8.7% |
|
- Biotech caught its own bid while the broad tape sold off: XBI ran +2.3% and NBI +1.5%, with GSK's $10.6B Nuvalent takeout and Parabilis' record $670M IPO handing the group catalysts the index didn't have.
- The broad tape sold off — S&P 500 (0.3%), Nasdaq Composite (1.0%) — after President Trump floated fresh strikes on Iran, reviving geopolitical risk and pushing the VIX up ~5% to ~19.9.
- Market data: U.S. cash close Tuesday, 9 June 2026.
The Big 3
|
1
|
GSK to acquire Nuvalent for $10.6B
|
- Nuvalent's ROS1 and ALK targeted cancer therapies anchor GSK's $10.6B buy, with both programs described as potentially approvable this year. Late-stage precision oncology still clears at full freight.
-
Why it matters: GSK's third bolt-on of 2026 and its biggest swing in over a decade. Miels is paying 40% over last close — NUVL jumped ~39% on the print — for two NSCLC drugs already sitting at the FDA, with neladalkib's verdict due 27 Nov. Accretion shows up in '27 on sales and '29 on EPS, so this isn't a science project. The signal for everyone else: a near-approval oncology asset with a clean launch path still commands full freight, and there aren't many of those left on the shelf. The catch is two FDA decisions standing between GSK and its first dollar of revenue.
-
Source:
STAT
-
More:
GSK release;
CNBC;
|
|
2
|
Parabilis prices record $670M biotech IPO
|
-
Parabilis (NASDAQ: PBLS) priced an upsized $670M IPO — 33.5M shares at $20 — the biggest biotech Nasdaq debut on record, funding Phase 3 of helicon-peptide zolucatetide in desmoid tumors. A concurrent $75M private placement to Regeneron at $18 rides alongside.
-
Why it matters: Biggest biotech IPO ever, past Kailera's $625M from April — and it priced upsized at $20, above the $17–19 range, which is the part that actually matters. Crossover money is back for scaled clinical-stage stories, and Regeneron writing a $75M check at $18 alongside says the Helicon platform travels well beyond the desmoid lead. If this holds, the late-stage private logjam starts clearing into debuts and follow-ons. The asterisk: it's basically one drug into a desmoid market SpringWorks' Ogsiveo already cracked, so the bull case rides on execution, not on raising money.
-
Source:
Endpoints
-
More:
Fierce Biotech;
BioPharma Dive;
|
| 3 | AstraZeneca's oral GLP-1 posts 11.8% weight loss, heads to Phase 3 |
-
AZ detailed Phase 2b data for elecoglipron, its oral small-molecule GLP-1: 11.8% mean weight loss at 36 weeks vs 0.3% for placebo in the Vista obesity trial (no plateau), and a 1.9% HbA1c drop in the Solstice diabetes trial. Pivotal Embold and Eluminate programs are now teed up.
-
Why it matters: AZ isn't the name anyone pencils into the GLP-1 bracket, which is exactly why the print lands. The 11.8% sits north of where rival oral small molecules have shown up — Jefferies said as much — and the GI profile reads ordinary, not scary. The drug it's really measured against is Lilly's orforglipron, and AZ wants to stack elecoglipron with Farxiga and its CSPC-sourced amylin into combos. The Street models barely $1B of AZ obesity sales by 2031, so a clean Phase 3 is upside nobody's paying for yet. The caveat writes itself: oral GLP-1s still have to hold up at scale, and the lane is crowded.
-
Source:
Fierce Biotech
-
More:
AstraZeneca;
|
Everything Else that broke
- EHA opened in Stockholm (11–14 June), with Karyopharm's Phase 3 SENTRY the marquee late-breaker — selinexor plus ruxolitinib showed an OS hazard ratio of 0.43 in JAKi-naïve myelofibrosis. — Oncology News Central
- FDA cleared EBGLYSS for every-8-week maintenance dosing in atopic dermatitis, supporting as few as six injections yearly. — PR
- Sanofi updated Phase 3 MOBILIZE for riliprubart in CIDP, keeping a key immunology asset under the microscope. — PR
- Biosecure fallout sharpened as WuXi AppTech prepared to challenge its Chinese military company designation. — BioCentury
- Applied Biologics cleared the FDA path to Phase 3 for BIOxHEAL in diabetic foot ulcers. — PR
- Antengene won China IND clearance for ATG-201, a CD19 × CD3 TCE, in autoimmune disease. — PR
- Harbour BioMed said China's NMPA accepted the IND for HBM7004 in advanced solid tumors. — PR
- Hikma outlined a $267M Ohio manufacturing expansion adding aseptic filling and oral solid dose capacity. — BioSpace
- Tevogen formed a healthcare services unit and said it may pursue MSO and CRO acquisitions. — PR
- Rakuten Medical named Minami Maeda CEO as it pushes toward a U.S. commercial launch. — PR
- Pacira shareholders elected all three company board nominees, easing a governance overhang. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
GSK agreed to buy Nuvalent for $10.6B, adding late-stage ROS1 and ALK oncology programs. — BioCentury
- Eli Lilly licensed AlzeCure's gamma-secretase modulator ACD860 for Alzheimer's: $10M upfront, up to $1B in milestones, tiered mid-single-digit royalties. — Fierce Biotech
VC / Private Financings
- No notable private financings in the last 24 hours.
IPOs / Follow-Ons
- Parabilis priced a $670M IPO for its cancer drug program. — Endpoints
- Shattuck Labs priced a $75M public offering at $4.00 per share plus pre-funded warrants. — PR
Academic Corner - Phase 1 data showed an adjuvanted rabies-vectored Lassa vaccine was safe and immunogenic in healthy adults. — Nature Medicine
- A review examined a decade of post-authorisation studies for medicines approved by the EMA. — Nature RDD
|
